Gadolinium-free extracellular MR contrast agent for tumor imaging
Joris Tchouala Nofiele 1 , Inga E Haedicke 2 , Yong Le Zhu 2 , Xiao-an Zhang 2 , and Hai-Ling Margaret Cheng 1,3
Hospital for Sick Children, Toronto,
University of Toronto, Toronto, Ontario, Canada,
of Biomaterials & Biomedical Engineering, University of
Toronto, Toronto, Ontario, Canada
Contrast administration is integral to tumor diagnostic
imaging, and gadolinium (Gd)-based contrast agents are
the current approved standard for clinical workflow.
However, a number of patients, particularly those with
impaired kidney function, are exempt from the benefits
of a contrast-enhanced examination. In this study, we
investigate the potential of a recently described novel
extracellular and renally filtered manganese porphyrin
T1 agent for tumor imaging. Results in tumor-bearing
rats demonstrate that the new agent, MnTCP, exhibits
similar pharmacokinetics but provides consistently
greater enhancement than Gd-DTPA. MnTCP can potentially
provide contrast-enhanced MRI for tumor diagnosis in a
broader patient base.
This abstract and the presentation materials are available to members only;
a login is required.